First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
01
03
2022
received:
07
11
2021
accepted:
04
03
2022
pubmed:
22
4
2022
medline:
28
7
2022
entrez:
21
4
2022
Statut:
ppublish
Résumé
Real-world data are limited on tenofovir alafenamide (TAF). We aimed to study TAF real-world outcomes with other first-line regimens for chronic hepatitis B (CHB). We enrolled patients with CHB from 10 centers retrospectively and followed them for 36 months prospectively. We analyzed switching patterns of antiviral therapy and treatment outcomes of TAF, tenofovir disoproxil fumarate (TDF), and entecavir therapy. For efficacy and safety, we analyzed a subset of patients with complete data at 24 months after switching to TAF or remaining on TDF or entecavir. Among 1037 enrollees, 889 patients were analyzed. The mean age was 52%, and 72% were hepatitis B e antigen-negative. After enrollment, shifts in therapies were mostly in reduced use of TDF from 63% to 30% due to switching to TAF. Clinical parameters were compared at enrollment or initiation to measures at 24 months for patients remaining on TAF (187), TDF (229), or entecavir (181). At 24 months, a significantly higher portion of patients on TAF achieved hepatitis B virus (HBV) DNA ≤ 20 IU/ml (93% vs. 86%; p = 0.012) and normalized alanine aminotransferase (ALT) (66% vs. 56%; p = 0.031) with stable estimated glomerular filtration rates (eGFRs). However, a higher percentage of the patient with eGFR < 60 ml/mi/1.7 m
Identifiants
pubmed: 35445803
doi: 10.1002/hep4.1964
pmc: PMC9315121
pii: 02009842-202208000-00005
doi:
Substances chimiques
Antiviral Agents
0
Tenofovir
99YXE507IL
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1881-1894Informations de copyright
© 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
Ghany MG, Perrillo R, Li R, Belle SH, Janssen HL, Terrault NA, et al. Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. Clin Gastroenterol Hepatol. 2015;13:183–92.
Pan CQ, Zhang JX. Natural history and clinical consequences of hepatitis B virus infection. Int J Med Sci. 2005;2:36–40.
Han GR, Jiang HX, Wang CM, Ding Y, Wang GJ, Yue X, et al. Long‐term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy. J Viral Hepat. 2017;24:514–21.
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83.
Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg‐positive chronic hepatitis B. N Engl J Med. 2006;354:1001–10.
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg‐negative chronic hepatitis B. N Engl J Med. 2006;354:1011–20.
Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg‐positive chronic hepatitis B virus infection: a randomised, double‐blind, phase 3, non‐inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185–95.
Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg‐negative chronic hepatitis B virus infection: a randomised, double‐blind, phase 3, non‐inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196–206.
Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–55.
Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real‐world evidence—what is it and what can it tell us? N Engl J Med. 2016;375:2293–7.
Franklin JM, Schneeweiss S. When and how can real world data analyses substitute for randomized controlled trials? Clin Pharmacol Ther. 2017;102:924–33.
Idilman R, Gunsar F, Koruk M, Keskin O, Meral CE, Gulsen M, et al. Long‐term entecavir or tenofovir disoproxil fumarate therapy in treatment‐naive chronic hepatitis B patients in the real‐world setting. J Viral Hepat. 2015;22:504–10.
Marcellin P, Zoulim F, Hezode C, Causse X, Roche B, Truchi R, et al. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3‐year, prospective, real‐world study in France. Dig Dis Sci. 2016;61:3072–83.
Petersen J, Heyne R, Mauss S, Schlaak J, Schiffelholz W, Eisenbach C, et al. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3‐year prospective field practice study in Germany. Dig Dis Sci. 2016;61:3061–71.
Jia J, Tang H, Ning Q, Jiang J, Dou X, Zhang M, et al. Real‐world evidence for nucleoside/nucleotide analogues in a 5‐year multicentre study of antiviral‐naive chronic hepatitis B patients in China: 52‐week results. Antivir Ther. 2018;23:201–9.
Kim CW, Kim CS, Kim HY, Lee CD, Yu K, Llamoso C, et al. Large‐scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B. Korean J Intern Med. 2018;33:91–101.
Lam YF, Seto WK, Wong D, Cheung KS, Fung J, Mak LY, et al. Seven‐year treatment outcome of entecavir in a real‐world cohort: effects on clinical parameters, HBsAg and HBcrAg levels. Clin Transl Gastroenterol. 2017;8:e125.
Sun Y, Zhang Y, Xu Y, Shu M, Bonroy K, Qiu H, et al. Real‐world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B. Epidemiol Infect. 2019;147:e193.
Wu X, Zhou J, Xie W, Ding H, Ou X, Chen G, et al. Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus‐related cirrhosis: a real‐world prospective multicenter cohort study. Infect Drug Resist. 2019;12:745–57.
Wong RJ, Nguyen MT, Trinh HN, Chan C, Huynh A, Ly MT, et al. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: a community‐based real‐world study. J Viral Hepatol. 2017;24:1089–97.
Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Ray Kim W, et al. Entecavir safety and effectiveness in a national cohort of treatment‐naive chronic hepatitis B patients in the US—the ENUMERATE study. Aliment Pharmacol Ther. 2016;43:134–44.
Lee HM, Ahn J, Kim WR, Lim JK, Nguyen M, Pan CQ, et al. A comparison between community and academic practices in the USA in the management of chronic hepatitis B patients receiving entecavir: results of the ENUMERATE study. Dig Dis Sci. 2019;64:358–66.
Developing the Next National Viral Hepatitis Strategy 2021–2025. https://www.hhs.gov/hepatitis/action‐plan/developing‐the‐next‐national‐viral‐hepatitis‐strategy/index.html . Accessed February 1, 2022.
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.
Stevens LA, Li S, Kurella Tamura M, Chen SC, Vassalotti JA, Norris KC, et al. Comparison of the CKD Epidemiology Collaboration (CKD‐EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011;57:S9–S16.
Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH‐B): development and validation of a predictive score. Lancet Oncol. 2011;12:568–74.
European Association for the Study of the Liver . Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(67):370–98.
Tong MJ, Pan CQ, Han SB, Lu DS, Raman S, Hu KQ, et al. An expert consensus for the management of chronic hepatitis B in Asian Americans. Aliment Pharmacol Ther. 2018;47:1181–200.
Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672–81.
Ogawa E, Nomura H, Nakamuta M, Furusyo N, Koyanagi T, Dohmen K, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020;40:1578–89.
Alghamdi AS, Alothmani HS, Mogharbel M, Albiladi H Sr, Babatin M. Clinical characteristics of hepatitis B virus patients after switching to tenofovir alafenamide fumarate: a retrospective observational study. Cureus. 2020;12:e10380.
Kaneko S, Kurosaki M, Tamaki N, Itakura J, Hayashi T, Kirino S, et al. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. J Gastroenterol Hepatol. 2019;34:2004–10.
Uchida Y, Nakao M, Tsuji S, Uemura H, Kouyama JI, Naiki K, et al. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate. J Med Virol. 2020;92:329–38.
Sun Y, Wu X, Zhou J, Meng T, Wang B, Chen S, et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy. Clin Gastroenterol Hepatol. 2020;18:2582–91.e6.
Kim JH, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, et al. Low‐level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology. 2017;66:335–43.
Choi J, Kim GA, Han S, Lim YS. Earlier alanine aminotransferase normalization during antiviral treatment is independently associated with lower risk of hepatocellular carcinoma in chronic hepatitis B. Am J Gastroenterol. 2020;115:406–14.
Wong GL, Chan HL, Tse YK, Yip TC, Lam KL, Lui GC, et al. Normal on‐treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. J Hepatol. 2018;69:793–802.